About Cytosurge
Cytosurge is a company based in Zurich (Switzerland) founded in 2009 by Michael Gabi and Pascal Behr. It operates as a B2B and D2C. Cytosurge offers products and services including FluidFM OMNIUM Platform, CellEDIT Service, and Online Quoter. Cytosurge operates in a competitive market with competitors including GSK, Avidity Biosciences, Sutro Biopharma, Antheia and Vividion Therapeutics, among others.
- Headquarter Zurich, Switzerland
- Founders Michael Gabi, Pascal Behr
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website cytosurge.com
- Social LinkedIn X Facebook
- Legal Name Cytosurge Ag
Products & Services of Cytosurge
Cytosurge offers a comprehensive portfolio of products and services, including FluidFM OMNIUM Platform, CellEDIT Service, and Online Quoter.
Platform for single-cell manipulation and biopsies
Service for CRISPR cell line engineering and knockouts
Tool for quoting cell editing services online
People of Cytosurge
10 people are tracked at Cytosurge (4 in leadership, 6 in team).
| Name | Role | Group |
|---|---|---|
Michael Gabi | Co-Founder, CTO | Leadership |
Pascal Behr | Co-Founder, CEO | Leadership |
Bernard Wasem | Ad-interim COO | Leadership |
Gregor Schuchter | Head Of Operations Instrument Business | Leadership |
Tamás Gerecsei | Instruments Sales Manager | Team |
Maria Milla | Customer Experience Manager | Team |
Michelle Curti | Salary Administration | Team |
Selina Schmid | HR Manager | Team |
Ronny Trippel | Technical Lead Systems Fulfillment | Team |
Anke Olschina | Production Technician | Team |
Complete people profiles for Cytosurge
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Competitors of Cytosurge
Cytosurge operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as GSK, Avidity Biosciences, Sutro Biopharma, Antheia and Vividion Therapeutics, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| gsk.com | 1715 | Brentford, United Kingdom | – | 90,913 | Developer of pharmaceuticals and vaccines for various therapeutic areas | |
| aviditybiosciences.com | 2012 | San Diego, United States | $142.54M | 253 | Antibody-siRNA complexes are developed for cancer treatment. | |
| sutrobio.com | 2003 | United States | $171.85M | 235 | Antibody-based therapeutics for cancer therapy are developed via cell-free synthesis. | |
| antheia.bio | 2013 | Palo Alto, United States | $152.37M | 50 | Yeast cells are genetically engineered to produce medicinal products. | |
| vividion.com | 2016 | Oceanside, United States | $270.5M | 123 | Developing novel drugs based on a proteome-wide ligand and target discovery platform | |
| synthego.com | 2012 | Redwood, United States | $459.75M | – | CRISPR-engineered cell and gene therapies are developed for research applications. | |
| korrobio.com | 2018 | Cambridge, United States | $4M | 77 | RNA-editing technologies are provided for precision medicine applications. | |
| univercells.com | 2013 | Charleroi, Belgium | $150.64M | 87 | Biomanufacturing technologies are supplied for biopharma antibody and vaccine production. | |
| savarapharma.com | 2008 | Austin, United States | $67.82M | 37 | Therapeutics for rare respiratory diseases are developed by Savara Pharma. | |
| lifeminetx.com | 2016 | Cambridge, United States | $300.07M | 85 | Developer of novel drugs from fungi via genome mining and recombinant overexpression |
Detailed competitors of Cytosurge
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Cytosurge
Complete news archive for Cytosurge
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to Cytosurge
10 companies that operate in the same segment as Cytosurge (Organ-on-Chip & Regenerative Solutions), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Human tissue-based products are developed for vascular disease applications. | 2004 | Morrisville, United States | USD 424.76 M | USD 2.04 M | 220 | |
Fish-skin acellular dermal matrix technology is provided for wound treatments. | 2007 | Isafjordur, Iceland | USD 93.11 M | – | 150 | |
Products for regenerative and respiratory medicine are developed and distributed. | 1992 | Cambridge, Cambridgeshire, United Kingdom | – | USD 71.61 M | 260 | |
Regenerative biomaterial products and bioimplants for wound, surgical, sports medicine and orthopedics | 1985 | Marietta, Georgia, United States | – | USD 418.63 M | 837 | |
Personalized skin tissue therapy is developed by CUTISS for surgeries. | 2017 | Zurich, Switzerland | USD 94.37 M | – | – | |
Synthetic adhesives for bone and dental repair are developed. | 2014 | Lowell, Massachusetts, United States | USD 24.42 M | – | – | |
Injectable synthetic bone substitutes are developed for fracture treatment. | 2000 | Lund, Sweden | USD 101.08 M | USD 127.04 M | 139 | |
Provider of in vivo stem cell modification technologies and vector-based drug delivery tool | 2019 | Boston, Massachusetts, United States | USD 205 M | – | 52 | |
Regenerative therapies for wound care are developed and commercialized. | 1985 | Canton, Ohio, United States | USD 30 M | USD 564.17 M | 869 | |
Reconstructive and regenerative solutions for bone conditions are developed. | 1980 | Lewisville, Texas, United States | – | USD 822.31 M | 1,620 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Cytosurge
Cytosurge was founded in 2009.
Cytosurge is headquartered in Zurich, Switzerland.
Pascal Behr is the current CEO of Cytosurge. They have also founded this company.
Cytosurge AG specializes in developing and providing FluidFM technology for precise single-cell injection, extraction, and biopsies in life sciences. The company offers products like the FluidFM OMNIUM Platform and services such as CellEDIT for CRISPR-based cell line engineering. Based in Switzerland, it serves researchers and institutions by bridging genetic design tools with practical applications, focusing on synthetic biology and therapy manufacturing.
Cytosurge's top competitors include Sutro Biopharma, Synthego and Avidity Biosciences.
Cytosurge offers FluidFM OMNIUM Platform, CellEDIT Service, and Online Quoter.
Cytosurge operates through Cytosurge Ag.